Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors.

ABSTRACT: Although the clinical efficacies of third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as osimertinib in the treatment of non-small cell lung cancer (NSCLC) with EGFR-activating mutations are promising, drug-acquired resistance inevitably occurs whether they are used as first-line or second-line treatment. Therefore, managing the acquired resistance to third-generation EGFR-TKIs is crucial in the clinic for improving patient survival. Great efforts have been made to develop potentially effective strategies or regimens for the treatment of EGFR-mutant NSCLC patients after relapse following these TKIs therapies with the hope that patients will continue to benefit from treatment through overcoming acquired resistance. Although this ap

SUBMITTER: Sun SY 

PROVIDER: S-EPMC10442612 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature